Osimertinib Global Buyers List: Complete Guide to Importers, Distributors & Procurement
Osimertinib—marketed under the brand name Tagrisso—has emerged as one of the most significant oncology drugs in the global pharmaceutical landscape. As a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, it is specifically designed to treat non-small cell lung cancer (NSCLC) patients with EGFR mutations. With the global Tagrisso market estimated at approximately USD 5.9 billion in 2024 and projected to grow at a compound annual growth rate of 4.85%, understanding the global buyer ecosystem for this life-saving medication has become essential for pharmaceutical suppliers, distributors, and healthcare stakeholders alike.
This comprehensive guide presents a detailed Osimertinib global buyers list, covering major importers, distributors, hospital procurement groups, and pharmaceutical companies across key markets.
1. Global Osimertinib Market Overview
Market Size and Growth Trajectory
The global Osimertinib drugs market has demonstrated remarkable growth, with the pharmaceutical-grade Osimertinib mesylate market valued at USD 1.56 billion in 2025. Projections indicate this market could reach USD 2.85 billion by 2034, exhibiting a CAGR of 6.8% during the forecast period. AstraZeneca maintains a dominant position as the sole manufacturer of Tagrisso, with annual sales exceeding USD 5 billion, supported by approvals in major markets including the United States, the European Union, Japan, and China.
Key Buying Regions
Osimertinib procurement is concentrated in several key regions:
- North America: The United States represents a major market, with FDA approvals continuously expanding Tagrisso indications.
- Europe: Countries including Spain, the Czech Republic, Poland, and Denmark have active tender processes for Osimertinib procurement.
- Asia-Pacific: China, Japan, India, Taiwan, and Southeast Asian nations demonstrate the highest growth rates, fueled by increasing healthcare access and high EGFR mutation rates in the region.
- Latin America: Brazil emerges as a significant importer, accounting for substantial Osimertinib trade volume.
- Middle East and Africa: Growing healthcare infrastructure supports increasing demand.
2. Major Osimertinib Importers & Buyers (Ranked by Import Value)
Based on verified customs data from Indian Directorate General of Foreign Trade (DGFT), here is a comprehensive ranking of active Osimertinib buyers and importers:
Top 15 Osimertinib Buyers
| Rank | Buyer Name | Country | Import Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | INDIRA GANDHI MEMORIAL HOSPITAL | Maldives | $130.8K | 12.0% |
| 2 | TO THE CONCERN PERSON | Brazil | $125.4K | 11.5% |
| 3 | INCEPTA PHARMACEUTICALS LTD | Bangladesh | $36.4K | 3.3% |
| 4 | CONCERN PERSON WANILDA DE | Brazil | $34.7K | 3.2% |
| 5 | TO THE | Brazil | $17.2K | 1.6% |
| 6 | GUILHERME MARTINS DE ALMEIDA | Brazil | $17.1K | 1.6% |
| 7 | TO THE | Brazil | $15.4K | 1.4% |
| 8 | LUIZ FRANCISCO GENRO SCHORN | Brazil | $12.8K | 1.2% |
| 9 | MARGARIDA ALVES DE SOUSA | Brazil | $12.8K | 1.2% |
| 10 | MARIZETE ALVES DE MORAES | Brazil | $12.8K | 1.2% |
| 11 | MARLENE ANTONIO DE SOUSA | Brazil | $12.8K | 1.2% |
| 12 | ADRIANE APARECIDA RODRIGUES DO NASC | Brazil | $12.6K | 1.2% |
| 13 | CONCERN PERSON GUILHERME MARTINS DE | Brazil | $12.5K | 1.1% |
| 14 | CONCERN PERSON LUIZ FRANCISCO GENRO SCHORN ENDERECO | Brazil | $12.0K | 1.1% |
| 15 | Additional buyers (35+ active importers) | Various | Various | Various |
Source: Indian Customs (DGFT) data, 2022–2026
Key Buyer Profiles
INDIRA GANDHI MEMORIAL HOSPITAL (MALDIVES) leads the global Osimertinib import market from India with a 12.0% share. The hospital sources Tagrisso 80mg tablets through established supplier relationships.
TO THE CONCERN PERSON (BRAZIL) ranks as the second-largest importer with $125.4K in import value across 16 verified shipments. This Brazilian pharmaceutical importer sources exclusively from NIVIRA EXPORTS and imports multiple formulations including LIFE SAVING MEDICINE-EACH FILM COATED TABLET CONTAINS: OSIMERTINIB MESYLATE 95.4MG EQ.TO OSIMERTINIB 80 MG.
INCEPTA PHARMACEUTICALS LTD (BANGLADESH) holds the third position with $36.4K in import value.
3. Osimertinib Distributors & Pharmaceutical Buyers
Global Pharmaceutical Distributors
Several pharmaceutical companies actively distribute Osimertinib across global markets:
- AstraZeneca Pharmaceuticals LP – The primary manufacturer and distributor of Tagrisso
- Incepta Pharmaceuticals Ltd – Major buyer and distributor in Bangladesh
- Beacon Pharmaceuticals Limited – Active in generic Osimertinib distribution
- Everest Pharmaceuticals – Regional distributor
- Drug International Limited – Pharmaceutical buyer and distributor
Generic Osimertinib Manufacturers & Suppliers
Multiple pharmaceutical companies have established manufacturing and supply capabilities for generic Osimertinib mesylate:
- Hetero Drugs – API and finished-dose manufacturing with a strong oncology footprint
- Intas Pharmaceuticals – Oncology generic manufacturing and supply presence
- Mylan (now Viatris) – API and finished-dose network in the generic Osimertinib market
- Sandoz (Novartis) – Finished-dose supply chain into generic markets
- Aurobindo Pharma – Generic Osimertinib tablet supplier
Chinese Osimertinib Suppliers
China has emerged as a significant supplier of Osimertinib mesylate:
- Zhejiang Ausun Pharmaceutical Co., Ltd – Supplies Osimertinib mesylate to buyers including Sushen Medicamentos Pvt Ltd in India
- Guangzhou Tonghui Pharmaceutical Co., Ltd – Provides global reference preparation procurement services for Osimertinib Mesylate Tablets
- Changzhou RuiMing Pharmaceutical Co., Ltd – Osimertinib supplier
- Changzhou Andyvok Medical Technology Co., Ltd – Osimertinib supplier
4. Hospital & Healthcare Procurement Buyers
Hospital procurement groups represent a significant segment of Osimertinib buyers globally. These organizations typically acquire Osimertinib through formal tender processes:
Taiwan Hospital Buyers
- Ministry of Health and Welfare Fengyuan Hospital – Multiple procurement tenders for Osimertinib成分藥品 (Osimertinib ingredient pharmaceuticals), with contract values reaching NT$9,072,000
- Ministry of Health and Welfare Tainan Hospital – Osimertinib tab. 80mg pharmaceutical procurement, contract value NT$9,979,200
European Hospital & Tender Buyers
- Faculty Thomayer Hospital (Czech Republic) – Tender for Drug Supply – Active Substance Osimertinib – Atc L01eb04
- Samodzielny Publiczny Szpital Kliniczny Nr 1 (Poland) – Tender for Osimertinib pharmaceutical products
- Amgros (Denmark) – Framework agreement for Tagrisso (Osimertinib) procurement to supply hospital pharmacies
Asia-Pacific Hospital Buyers
- Lopburi Cancer Hospital (Thailand) – Osimertinib 80 mg tab procurement plan
5. Osimertinib Supply Chain: Suppliers to Global Buyers
Understanding the supply chain network is crucial for identifying potential buyer-seller relationships. Based on Indian DGFT data, here are the top Osimertinib exporters and their buyer networks:
Top Osimertinib Suppliers from India
| Rank | Supplier Name | Export Value (USD) | Market Share |
|---|---|---|---|
| 1 | NU HOSPITALS PRIVATE LIMITED | $264.1K | 24.2% |
| 2 | NIVIRA EXPORTS | $202.9K | 18.6% |
| 3 | IKRIS PHARMA NETWORK PRIVATE LIMITED | $130.8K | 12.0% |
| 4 | MATSUN EXPORTS | $76.3K | 7.0% |
| 5 | VAMA LIFECARE PRIVATE LIMITED | $49.5K | 4.5% |
| 6 | YARAPMIN PHARMA PRIVATE LIMITED | $35.4K | 3.2% |
Source: Indian Customs (DGFT) shipping bill records
Supplier-Buyer Relationships
- NU HOSPITALS PRIVATE LIMITED serves FOR THE ORDER OF with $264.1K across 4 shipments
- NIVIRA EXPORTS is the exclusive supplier to TO THE CONCERN PERSON (Brazil) with $125.4K across 16 shipments
- IKRIS PHARMA NETWORK PRIVATE LIMITED supplies INDIRA GANDHI MEMORIAL HOSPITAL (Maldives)
- VAMA LIFECARE PRIVATE LIMITED serves 11 named purchasing companies across 8+ countries
6. How to Identify and Connect with Osimertinib Buyers
Recommended Approaches
1. Utilize Trade Data Platforms
Platforms like TransData Nexus, 52wmb.com, and Volza provide access to customs data showing actual buyer-seller relationships, shipment values, and product specifications.
2. Monitor Tender Notifications
Government procurement portals and tender platforms regularly publish Osimertinib procurement notices. Key sources include Taiwan Procurement Gazette, European Tenders Electronic Daily, and national health ministry procurement systems.
3. Partner with Established Distributors
Engaging with established pharmaceutical distributors like Incepta Pharmaceuticals, Beacon Pharmaceuticals, and Everest Pharmaceuticals can provide access to established buyer networks.
4. Attend Pharmaceutical Trade Shows
Major oncology and pharmaceutical trade events provide networking opportunities with global buyers and distributors.
5. Regulatory Compliance
Ensure compliance with local pharmaceutical import regulations, including:
- Product registration and marketing authorization
- Good Distribution Practice (GDP) certification
- Cold chain logistics capabilities where required
- Proper documentation for customs clearance
7. Key Considerations for Osimertinib Sourcing
Regulatory Requirements
Osimertinib is a prescription-only medication requiring regulatory approval in most markets. Buyers typically include hospitals, registered pharmaceutical companies, and authorized distributors.
Pricing and Reimbursement
Pricing pressures and payer reimbursement policies represent significant market challenges. Patent protection in key regions remains until the early 2030s.
Quality Standards
Buyers increasingly demand:
- WHO-GMP certified manufacturing
- Bioequivalence studies for generic versions
- Stable supply chain with documented cold chain management
- Regulatory dossier support for product registration
8. Future Outlook for Osimertinib Global Buyers
The Osimertinib market continues to expand, driven by:
- Rising incidence of NSCLC, particularly in Asia where EGFR mutation rates are high
- Expanded indications including adjuvant therapy following tumor resection
- Combination regimens with chemotherapy
- Growing healthcare access in emerging markets
The pharmaceutical-grade Osimertinib mesylate market is projected to grow from USD 1.69 billion in 2026 to USD 2.85 billion by 2034, creating substantial opportunities for suppliers and distributors entering this market.
BỆNH VIỆN K
BỆNH VIỆN PHỔI TRUNG ƯƠNG
BỆNH VIỆN UNG BƯỚU
CÔNG TY TNHH ASTRAZENECA VIỆT NAM
JOHNSON JOHNSON PRIVATE LIMITED
RENATA PLC CHANGED FROM RENATA
ASTRAZENECA PHARMA INDIA LIMITED
WATSON PHARMA PRIVATE LIMITED
CÔNG TY TNHH SẢN XUẤT NAVIS VIỆT NAM
ASTRAZENECA PERU S A
ASTRAZENEZA S A
D H L KEELS PVT LTD
INCEPTA PHARMACEUTICALS LIMITED
JANSSEN CILAG SA DE CV
ASTRAZENECA SA DE CV
EVEREST PHARMACEUTICALS LIMITED
SULE MENE SAGLIK ARASTIRMA EGITIM DANISMANLIK BILISIM SANAYI TICARET ANONIM SIRKETI
SUSHEN MEDICAMENTOS PRIVATE LIMITED
DHL KEELLS PVT LTD
JENPHAR BANGLADESH LIMITED CHANGED
ASTRAZENECA COLOMBIA SAS
ASTRAZENECA INDUSTRIES LLC
CLIANTHA RESEARCH LIMITED
HIMMEL PHARMACEUTICALS PVT LIMITED
PAREXEL CLINICAL RESEARCH
GENERICS AFRICA LIMITED
MSN LABORATORIES PRIVATE LIMITED
WORLD MEDICINE ILAC SANAYI VE TICARET ANONIM SIRKETI
101 SUPPLY CHAIN SOLUTIONS INC
ALLIANZ BIOINNOVATION
ASTRAZENECA PHARMACEUTICALS PHILIPPINES
DRUG INTERNATIONAL LIMITED
JOHNSON AND JOHNSON SIHHI MALZEME SANAYI VE TICARET LIMITED SIRKETI
ONCOGEN PHARMA PRIVATE LIMITED
SIGMA ALDRICH CHEMICALS PRIVATE LIMITED
TORRENT PHARMACEUTICALS LTD
ALKEM LABORATORIES LIMITED
ASTRAZENECA PHARMACEUTICALS PHILS
CÔNG TY TNHH MTV NOVALAB
DEVA HOLDING ANONIM SIRKETI
FISHER BIOPHARMA SERVICES INDIA PVT LTD
HILDA WANGU MWAI
JOHNSON AND JOHNSON PRIVATE LIMITED
BIO PHARMA LTD CHANGED FROM BIO
BIOMEDICAL LIFE SCIENCES
CIPLA LIMITED
CÔNG TY CP DƯỢC MINH HẢI
CÔNG TY CỔ PHẦN DƯỢC PHẨM ĐẠT VI PHÚ
DRUGLAND CORPORATION
HEALTHCARE PHARMACEUTICALS LTD
INTAS PHARMACEUTICALS LIMITED
KAIZEN PHARMACEUTICALS PVT LTD
LABORATORIO LIBRA S A
NON COMMERCIAL IMPORTER
ONCOGEN PHARMA PVT LTD
PAREXEL CLINICAL RESEARCH PHILIPPI
PAREXEL INTERNATIONAL CLINICAL RESEARCH PRIVATE LI
QUIMFA S A
ZISKA PHARMACEUTICALSLIMITED
ZIVA ORGANIC BANGLADESH
ZYDUS LIFESCIENCES LIMITED
ООО АСТРАЗЕНЕКА ИНДАСТРИЗ
ABDI IBRAHIM ILAC SANAYI VE TICARET ANONIM SIRKETI
ALEMBIC PHARMACEUTICALS LIMITED
ASTRAZENECA PHARMACEUTICALS LP
BIOORGANICS AND APPLIED MATERIALS PRIVATE LIMITED
CLEARSYNTH LABS LIMITED
CÔNG TY CỔ PHẦN DƯỢC TRANG THIẾT BỊ Y TẾ BÌNH ĐỊNH BIDIPHAR
CÔNG TY CỔ PHẦN KỸ THUẬT VÀ SINH HỌC ỨNG DỤNG VIỆT NAM
CÔNG TY TRÁCH NHIỆM HỮU HẠN SINH DƯỢC PHẨM HERA
DHL PAKISTAN PRIVATE LIMITED
DR REDDY S LABORATORIES LTD
ECOVIDA S A
ESKAYEF PHARMACEUTICALS LIMITED
HETERO LABS LIMITED
JANSSEN PHARMACEUTICA NV BELGIUM MOSCOW REP OFFICE
JULIE CORAZON PO
LAB FRANCO COLOMBIANO LAFRANCOL S A S
LAB LIBRA
MARINELLA P LOPEZ
MUHAMMAD ARSHAD
NOVEAULAB ASIA CORP
ONCOPHARM U LTD
ONCOVANZ PHARMACEUTICALS PRIVATE LIMITED
ONE PHARMA LIMITED
PHARMACIL LIMITED
SALMA AZIZ C O MOHAMMAD NAZMUL HASSAN
SIMSON PHARMA LIMITED
V M G HEALTHCARE PRODUCTS SOCIEDAD ANONIMA
VMG HEALTH CARE PRODUCTS S A
ПРЕДСТАВНИЦТВО ЯНССЕН ФАРМАЦЕВТИКА НВ 04070 МІСТО КИЇВ ВУЛИЦЯ СПАСЬКА БУДИНОК 30 УКРАЇНА
ПРЕДСТАВНИЦТВО ЯНССЕН ФАРМАЦЕВТИКА НВ ВУЛ СПАСЬКА 30 КИЇВ 04070 УКРАЇНА
Conclusion
The global Osimertinib buyer ecosystem encompasses diverse stakeholders including hospital procurement groups, pharmaceutical distributors, generic manufacturers, and specialized importers across more than 50 countries. Brazil, Maldives, Bangladesh, and Taiwan represent key buying markets, while India and China emerge as significant supply sources.
For pharmaceutical companies, distributors, and suppliers seeking to enter or expand in the Osimertinib market, understanding this buyer landscape is essential for successful market penetration. By leveraging trade data, monitoring tender opportunities, and building relationships with established distributors, suppliers can effectively connect with qualified Osimertinib buyers worldwide.
Disclaimer: This article is for informational purposes only. All trade data is sourced from publicly available customs records and may not represent complete market activity. Readers should verify all information independently and ensure compliance with applicable laws and regulations in their respective jurisdictions.
